Back to Agenda
Start–Ups Meet Regulatory and Industry – How Can Ideas from Academia Be Best Translated to Novel Treatment Options? What Kind of Partnerships Are Required?
Session Chair(s)
Michael Brandkamp
Managing Director
High-Tech Gruenderfonds, Germany
Young biotech companies are faced with a plethora of challenges nowadays. Not only do they have to find the money to pursue their research, but also to navigate in an increasingly complex regulatory environment. The panel will discuss what partnerships are required to successfully translate disruptive novel ideas into novel treatment options
Speaker(s)
Presentation
Melanie Carr
European Medicines Agency, Netherlands
Head of Stakeholders and Communication Division
Andreas Schmidt, DrSc
AYOXXA Biosystems, Germany
CEO
New Treatment Paradigms – Regulatory Challenges for SMEs
Ulrich Dauer, DrSc
OMEICOS, Germany
CEO
Presentation
Sam Wadsworth, PhD
Dimension Therapeutics, United States
Chief Scientific Officer
The Role of Venture Funds in Enabling Innovation
Frank Kalkbrenner
Boehringer Ingelheim Venture Fund, Germany
Corporate Vice President
The Role of Industry in the Innovation Ecosystem
Joseph Scheeren, PharmD
Scheeren HealthCare LLC, United States
Founder
Have an account?